DexCom, Inc. (NASDAQ:DXCM – Get Free Report) Director Steven R. Altman sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $101.50, for a total value of $101,500.00. Following the sale, the director now directly owns 61,700 shares in the company, valued at approximately $6,262,550. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
DexCom Trading Down 1.2 %
Shares of NASDAQ DXCM traded down $1.13 during trading hours on Tuesday, reaching $94.16. The stock had a trading volume of 3,644,366 shares, compared to its average volume of 2,849,918. DexCom, Inc. has a 52-week low of $78.94 and a 52-week high of $139.55. The firm has a market cap of $36.52 billion, a price-to-earnings ratio of 109.72, a P/E/G ratio of 1.82 and a beta of 1.12. The business’s fifty day moving average price is $114.89 and its two-hundred day moving average price is $118.10. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 1.16.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.12. The business had revenue of $871.30 million for the quarter, compared to the consensus estimate of $841.16 million. DexCom had a return on equity of 22.01% and a net margin of 11.18%. The business’s revenue was up 25.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.17 EPS. Analysts expect that DexCom, Inc. will post 1.23 EPS for the current fiscal year.
Hedge Funds Weigh In On DexCom
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Canaccord Genuity Group increased their price objective on shares of DexCom from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, July 28th. Piper Sandler lifted their price objective on DexCom from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. Morgan Stanley initiated coverage on DexCom in a research report on Tuesday, May 30th. They set an “equal weight” rating and a $131.00 target price for the company. Robert W. Baird reduced their price target on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating on the stock in a research report on Monday, August 21st. Finally, Barclays increased their price objective on shares of DexCom from $115.00 to $138.00 and gave the company an “equal weight” rating in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $136.31.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
- Five stocks we like better than DexCom
- What Is WallStreetBets and What Stocks Are They Targeting?
- Hold-It-Forever AutoZone Pulls into Buy Zone
- Stock Analyst Ratings and Canadian Analyst Ratings
- Virtual Riches: 3 Stocks Leading the VR Revolution
- How to Invest in Solar Energy
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.